ProfileGDS5678 / 1440166_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 21% 21% 20% 20% 20% 20% 22% 20% 19% 20% 20% 20% 20% 20% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5153421
GSM967853U87-EV human glioblastoma xenograft - Control 22.4855421
GSM967854U87-EV human glioblastoma xenograft - Control 32.4793420
GSM967855U87-EV human glioblastoma xenograft - Control 42.4186520
GSM967856U87-EV human glioblastoma xenograft - Control 52.4213720
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5425320
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5477122
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4547620
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4321819
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4728320
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4709120
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.457420
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4784820
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4733920